BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FD
Posted Jan 14 2009 8:24pm
Article contributed by Olga R., in Miami
Toronto Stock Exchange Symbol: MS
EDMONTON, Sept. 4 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.
Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog. ============================================